SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the main focus, with traders watching guidance, subscriber engagement and advertising growth amid a steep share-price decline. Bears point to content concerns, competition and past post-earnings drops, while bulls argue low expectations and a stronger outlook could support a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious next chapter remarks have fueled buyout speculation, while traders are focused on the Phase 3 REGAL AML trials pending 80th-event trigger and eventual results; no acquisition or data leak is confirmed. The rebound has drawn bullish calls, but others view it as volatile, news-free trading and stress that the trial outcome remains uncertain.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being discussed amid broader neocloud concerns about financing, AI infrastructure spending returns, and whether providers can remain independent; traders also point to dilution and possible project delays. The community is split between bearish views that the weakness may persist and bullish arguments that IRENs cash-funded data centers and customer prepayments distinguish it from more debt-heavy peers.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings and guidance are dominating discussion, especially whether AI and data-center growth can support heavy capital spending and a return to profitability. Traders are divided between expecting a strong report and worrying that rising spending, financing needs, and an approaching share unlock could weigh on the stock.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a quarterly earnings beat as investors focus on a narrowed full-year profit outlook with its midpoint unchanged; the new buyback and stronger cash-flow outlook have not offset that concern. Traders are split between buying the dip on capital returns and value, and expecting more downside over cautious guidance and demand pressures.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPT is rising alongside a broader biotech rebound, while traders also cite the Silence Therapeutics acquisition as a positive read-through for demand for siRNA therapiesa platform in Sareptas pipeline. The community is split on whether the move reflects sector strength or stock-specific buying, with upcoming DM1 and FSHD data adding to optimism but no new Sarepta catalyst confirmed.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Traders are focused on the full Phase 3 data for Moderna and Mercks personalized melanoma vaccine at ESMO, following a positive topline result and a sharp rally. Bulls see validation of Modernas cancer-vaccine platform, while skeptics argue expectations and valuation are stretched and warn of a possible sell-the-news reaction.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets weak price action and difficulty sustaining rebounds dominate discussion, with traders linking pressure to the broader tech and AI selloff and weighing cloud growth against heavy AI spending and cash-flow concerns ahead of earnings. Bulls see the pullback as a buying opportunity, while bears point to technical weakness and capex risks.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas steep selloff is being tied to uncertainty over a potential Monee public listing and the planned Sea Cloud venture, with traders concerned about added spending, execution risk and Shopees competition. Some see a Monee listing as value-unlocking and view the decline as a buying opportunity, while others fear it leaves Seas remaining business less attractive.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders debating whether Google Cloud and Gemini growth can justify heavy AI investment. Speculation that capital spending could rise sharply is fueling concerns about returns and pressure on the shares, while bulls expect strong results and see the pullback as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

What's Going On With Black Diamond Therapeutics Stock Tuesday?

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.read more...

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.

Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday

Black Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-black-diamond-therapeutics-inc-stock...

HC Wainwright Issues Positive Forecast for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright upped their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Wednesday...

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Investors need to pay close attention to BDTX stock based on the movements in the options market lately.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Black Diamond Therapeutics Inc

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

Equity

Bullish Sentiment

Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/servier-and-black-diamond-therapeutics-announce-global-licensing">licensing agreement</a> with Servier, a French pharmaceutical group.As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.Under the agreement, Black Diamond will receive an upfront payment of $70 million and can receive up to $710 million in future payments, including development and commercial sales milestone payments and tiered royalties based on net sales.The company said earlier this month that its cash, cash equivalents, and investment of $98.6 million as of the end of 2024 would be sufficient to fund operations and capital expenditure requirements into the last quarter of 2026.On Stocktwits, retail sentiment around Black Diamond’s stock rose to a year-high, jumping higher within the ‘extremely bullish’ territory (100/100). Meanwhile, message volume surged to ‘extremely high’ levels from ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:810/187;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_140848_png_e163bd613a.webp" alt="Black Diamond Therapeutics' Sentiment Meter and Message Volume as of 2:00 p.m. ET on March 19, 2025 | Source: Stocktwits" width="810" height="187"><figcaption>Black Diamond Therapeutics' Sentiment Meter and Message Volume as of 2:00 p.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the shares rising as high as $6 from its current value of over $2.&nbsp;<stembedurl>https://stocktwits.com/DaSqueeza/message/608568813</stembedurl>Another opined that a “strong reversal” is coming for the stock.<stembedurl>https://stocktwits.com/alecsalaur198/message/608560099</stembedurl><a href="https://stocktwits.com/symbol/BDTX">Black Diamond shares</a> are down by over 50% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$2.11
Prev Close	$1.81
Open	$1.83
Dividend Yield	0.00%
50-Day Moving Average	$1.98
Beta	1.73
Avg. Volume	588,308.74
PE Ratio	-2.43

52-Week High	$4.94
52-Week Low	$1.60
Market Capitalization	$103.99M
EPS (Annual)	$0.3886
Price to Book	1.08
Revenue Per Employee	$3.33M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BDTX Fundamentals